Australia markets open in 7 hours 1 minute

CytomX Therapeutics, Inc. (CTMX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
1.8500-0.0200 (-1.07%)
As of 12:57PM EDT. Market open.
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
16,533
-569
-99,317
-115,870
-64,820
-
Depreciation & amortisation
2,047
2,175
2,443
2,706
2,573
-
Deferred income taxes
-
-
-
-
-
0
Stock-based compensation
8,056
8,558
13,125
13,167
14,786
-
Change in working capital
-114,129
-62,509
-30,654
-22,439
50,069
-
Accounts receivable
-12,087
32,554
-35,196
8
-785
-
Accounts payable
-227
-1,426
68
-139
-857
-
Other working capital
-92,336
-56,875
-112,528
-120,640
2,950
-
Other non-cash items
3,814
3,729
3,413
3,133
2,887
-
Net cash provided by operating activities
-91,429
-56,035
-110,788
-119,031
5,259
-
Cash flows from investing activities
Investments in property, plant and equipment
-907
-840
-1,740
-1,609
-2,309
-
Purchases of investments
-278,240
-424,834
0
-99,898
-199,108
-
Sales/maturities of investments
320,000
275,000
100,000
123,996
182,699
-
Net cash used for investing activities
40,853
-150,674
98,260
22,489
-18,718
-
Cash flows from financing activities
Common stock issued
-
-
0
107,712
11,288
0
Net cash used provided by (used for) financing activities
30,404
30,230
648
110,213
16,893
-
Net change in cash
-20,172
-176,479
-11,880
13,671
3,434
-
Cash at beginning of period
57,274
194,567
206,447
192,776
189,342
-
Cash at end of period
37,102
18,088
194,567
206,447
192,776
-
Free cash flow
Operating cash flow
-91,429
-56,035
-110,788
-119,031
5,259
-
Capital expenditure
-907
-840
-1,740
-1,609
-2,309
-
Free cash flow
-92,336
-56,875
-112,528
-120,640
2,950
-